Lowest Price Guaranteed
Pages
183
Last Updated
June 2026
View Count
12582
Chapter 2 provides an executive summary of the report. It offers a high level view on the present scenario of dendrimers and polymer drug conjugates and where they are headed in the mid to long term.
Chapter 3 provides a general introduction to nanotechnology with a detailed discussion on its applications in the biopharmaceutical industry. This chapter discusses the various types of nanocarriers that have revolutionized drug delivery and other biomedical applications.
Chapter 4 includes information on nearly 40 polymer drug conjugates that are being evaluated in different stages of development (both clinical and preclinical/discovery). In this chapter, we have identified the companies that are active in this market and conducted a detailed pipeline analysis including information on type of polymers, type of drugs, most commonly targeted indications and the phase of development. In addition, we have provided a list of the different classes of dendrimers highlighting their developer, core molecules and surface groups.
Chapter 5 provides an in-depth introduction to dendrimers. In this chapter, we have captured the most popular dendrimers used for development of diagnostics, therapeutics and other biomedical products; these are accompanied with detailed information on their structure, research applications and detailed product profiles of the commercialized products.
Chapter 6 comprises of a comprehensive discussion on the advantages, applications and target disease areas of polymer drug conjugates. In addition, the chapter gives detailed profiles of phase III and phase II molecules including information of their developer, clinical trials and primary/secondary endpoints.
Chapter 7 offers a comprehensive view on the market forecast of polymer drug conjugates measuring the opportunity in the next ten years. Due to the uncertainty surrounding some of the key assumptions, we have presented three different evolution scenarios for the overall market. In addition, we have presented a qualitative analysis of the opportunity areas of dendrimers highlighting their future potential.
Chapter 8 summarizes the overall report. In this chapter, we have provided a recap of the key take aways and our overall opinion on where the market is headed in the mid-long term.
Chapter 9 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.
Chapter 10 is an appendix, which provides a list of companies and organizations mentioned in the report.
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. The Concept of Nanotechnology
3.2. Nanomedicine: A Potential Platform for Therapeutic Applications
3.3. Applications of Nanomedicine
3.3.1. Drug Delivery
3.3.2. Diagnostic Techniques
3.3.3. Anti-Microbial Techniques
3.3.4. Therapeutic Techniques
3.3.5. Surgery
3.3.6. Gene Therapy
3.3.7. Imaging
3.4. Nanocarriers: Important Tools for Nanomedicine
3.4.1. Nanoparticles
3.4.2. Carbon Nanotubes (CNTs)
3.4.3. Polymer Conjugates
3.4.4. Nanocrystals
3.4.5. Dendrimers
3.5. Nanocarriers and Drug Approvals
4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Dendrimers: Product List and Classes
4.3. Polymer Drug Conjugates: Development Pipeline
4.3.1. Distribution by Phase of Development
4.3.2. Distribution by Type of Disease Area
4.3.3. Distribution by Type of Polymer
4.3.4. Distribution by Type of Drug
4.3.5. Leading Players of the Industry
5.DENDRIMERS: A DETAILED REVIEW
5.1. An Introduction to Dendrimers
5.2. Synthesis of Dendrimers
5.2.1. Divergent Mode of Synthesis
5.2.2. Convergent Mode of Synthesis
5.3. Characterization of Dendrimers
5.3.1. Spectroscopic Techniques
5.3.2. Microscopy
5.3.3. Size Exclusion Chromatography
5.3.4. Other Techniques
5.4. Properties of Dendrimers
5.5. Advantages of Dendrimers
5.6. Applications of Dendrimers
5.6.1. Drug Delivery
5.6.2. Mimics of Globular Proteins
5.6.3. Gene Transfection
5.6.4. Imaging and Diagnostics
5.6.5. Solubility Enhancers
5.6.6. Modification of Electrodes
5.6.7. Development of Vaccines
5.7. Classification of Dendrimers
5.8. Types of Dendrimers
5.9. Commercialized Dendrimers
5.9.1. PAMAM/Starburst®
5.9.1.1. Specifications
5.9.1.2. Structure and Synthesis
5.9.1.3. Properties
5.9.1.4. Products Based on PAMAM
5.9.1.5. PAMAM: Application in Biopharmaceuticals
5.9.2. Poly-L-Lysine (PLL) Dendrimers (Multiple Antigen Peptide Dendrimers)
5.9.2.1. Specifications
5.9.2.2. Structure
5.9.2.3. Products Based on PLL Dendrimers
5.9.3. Priostar® Dendrimers (Frechet Type Dendrimers)
5.9.3.1. Specifications
5.9.3.2. Priostar® : Applications
5.9.3.3. Products Based on Priostar® Dendrimers
5.9.4. Astramol® (Polypropylenimine (PPI) Dendrimer)
5.9.4.1. Specifications
6.POLYMER DRUG CONJUGATES: DRUG PROFILES
6.1. The Rationale of Polymer Drug Conjugates
6.2. Designing and Characterization of Polymer Drug Conjugates
6.3. Most Common Polymers
6.4. Most Common Drugs
6.5. Advantages of Polymer Drug Conjugates
6.6. Polymer Drug Conjugates in Oncology and Other Diseases
6.7. Polymer Drug Conjugates: Drug Profiles
6.7.1. Nektar Therapeutics
6.7.1.1. Company Overview
6.7.1.2. Product Profile: NKTR-102 / EtirinotecanPegol
6.7.1.3. Product Profile: NKTR-181
6.7.2. CTI BioPharma
6.7.2.1. Company Overview
6.7.2.2. Product Profile: Opaxio™
6.7.3. Cerulean Pharma
6.7.3.1. Company Overview
6.7.3.2. Product Profile: CRLX101
7. MARKET FORECAST AND OPPORTUNITY ANALYSIS
7.1. Chapter Overview
7.2. Polymer Drug Conjugates: Future Projections
7.2.1. Scope and Limitations
7.2.2. Forecast Methodology
7.2.3. Polymer Drug Conjugates Market, Late Clinical Molecules (USD Million): 2016-2026 (Base Scenario)
7.2.3.1. NKTR-118 (Nektar Therapeutics)
7.2.3.2. NKTR-102 (Nektar Therapeutics)
7.2.3.3. CRLX101 (Cerulean Pharma)
7.2.3.4. Opaxio™ (CTI BioPharma)
7.3. Dendrimers: Opportunity Areas
7.3.1. Drug Delivery Systems
7.3.2. Research Applications
7.3.3. Therapeutic Applications
7.3.4. Diagnostic Applications
8. CONCLUSION
8.1. The Evolving Era of Polymer Therapeutics Offers Significant Promise to the Pharmaceuticals Market
8.2. Amongst all the Applications, Drug Delivery Holds a Large Opportunity
8.3. The Dendrimer Market is Yet to Unveil itsPotential in the Biomedical Industry
8.4. Polymer Drug Conjugates are Being Exploited for Numerous Therapeutic Areas
8.5. With Success of the Already Commercialized Drugs, the Next Generation of Polymer Drug Conjugates are Poised to Witness an Accelerated Growth
9. APPENDIX 1: TABULATED DATA
10. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
Figure 3.1 Application of Nanomedicines
Figure 3.2 Nanomedicine Drug Delivery: Applications in Key Therapeutic Areas
Figure 3.3 Challenges Associated with Drug Delivery in Nanotechnology
Figure 3.4 Classification of Nanocarriers
Figure 3.5 Properties of Carbon Nanotubes
Figure 3.6 Properties of Dendrimers
Figure 4.1 Pipeline Analysis: Distribution by Phase of Development
Figure 4.2 Pipeline Analysis: Distribution by Type of Disease Area
Figure 4.3 Pipeline Analysis: Distribution by Type of Polymer
Figure 4.4 Pipeline Analysis: Distribution by Type of Drug
Figure 4.5 Polymer Drug Conjugates: Key Players
Figure 5.1 Dendrimers: Advantages
Figure 5.2 Dendrimer versus Linear Polymers
Figure 5.3 Dendrimers: Classification
Figure 5.4 Dendrimers: Types
Figure 5.5 SuperFect® Transfection Reagent: Applications
Figure 5.6 SuperFect® Transfection Reagent: Protocol
Figure 5.7 Polyfect® Transfection Reagent: Protocol
Figure 5.8 PrioFect™: Clinical and Non-Clinical Applications
Figure 5.9 NanoJuice®Transfection Kit: Advantages
Figure 6.1 Polymer Drug Conjugates: Ringsdorf Model
Figure 6.2 Polymer Drug Conjugates: Advantages
Figure 6.3 Application of Polymer Drug Conjugates in Several Indications
Figure 6.4 Nektar Therapeutics: Annual Revenue, 2010-2015 (USD Million)
Figure 6.5 PEGylatedIrinotecan: NKTR-102
Figure 6.6 NKTR-102: Mechanism of Action
Figure 6.7 Advantages of NKTR-102 over Irinotecan
Figure 7.1 Polymer Drug Conjugates Market, Late Clinical Molecules (USD Million): 2016-2026 (Base Scenario)
Figure 7.2 Polymer Drug Conjugates Market: Share of Lead Molecules in 2026 (USD Million, %)
Figure 7.3 NKTR-181 Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Base Scenario)
Figure 7.4 NKTR-181 Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Base Scenario)
Figure 7.5 NKTR-102 Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Base Scenario)
Figure 7.6 NKTR-102 Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Base Scenario)
Figure 7.7 CRLX101 Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Base Scenario)
Figure 7.8 CRLX101 Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Base Scenario)
Figure 7.9 Opaxio™ Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Base Scenario)
Figure 7.10 Opaxio™ Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Base Scenario)
Figure 7.11 Collaboration Based Revenues: Illustrative Future Projections
Figure 8.1 Polymer Therapeutics versus Conventional Therapeutics
Figure 8.2 Polymer Drug Conjugates: Emerging Therapeutic Areas
Figure 8.3 Polymer Drug Conjugates Market, Late Clinical Molecules (USD Million): 2017, 2021, 2026
Table 3.1 Approved Nanocrystal Drugs
Table 3.2 List of Commercialized Nanomedicines
Table 4.1 Dendrimers: Product List and Classes
Table 4.2 Polymer Drug Conjugates: Development Pipeline
Table 5.1 List of Drugs Loaded in Dendrimers
Table 5.2 List of Commercialized Dendrimers
Table 5.3 Dendritech: List of PAMAM Dendrimers
Table 5.4 Stratus® CS: Type of Biomarkers
Table 5.5 SuperFect™ Transfection Reagent: Product Details
Table 5.6 PolyFect™ Transfection Reagent: Product Details
Table 5.7 PolyFect™ Transfection Reagent: Product Details
Table 5.8 PAMAM: Biotherapeutic Applications
Table 5.9 VivaGel®: Current Status of Development
Table 5.10 VivaGel®: Current Status of Development
Table 5.11 VivaGel®: Clinical Trial Endpoints
Table 5.12 Gadomer-17: Product Specifications
Table 5.13 PPI Dendrimers: Price and Quantity
Table 6.1 Approved Polymer Drug Conjugates
Table 6.2 Polymer Drug Conjugates: Profiled Drugs
Table 6.3 NKTR-102: Current Status of Development
Table 6.4 NKTR-102: Clinical Trials
Table 6.5 NKTR-102: Phase II Clinical Trial Endpoints (Breast Cancer, Ovarian Cancer, Colorectal Cancer, Lung Cancer)
Table 6.6 NKTR-102: Phase II Clinical Trial Endpoints (Glioma, Solid Tumors)
Table 6.7 NKTR-102 versus TPC: Adverse Events
Table 6.8 NKTR-181: Current Status of Development
Table 6.9 NKTR-181: Clinical Trials
Table 6.10 NKTR-181: Clinical Trials
Table 6.11 Opaxio™: Current Status of Development
Table 6.12 Opaxio™: Clinical Studies
Table 6.13 Opaxio™: Clinical Trial Endpoints for Ovarian Epithelial, Peritoneal and Fallopian Tube Cancer
Table 6.14 Opaxio™: Clinical Trial Endpoints for Other Indications
Table 6.15 CRLX101: Current Status of Development
Table 6.16 CRLX101: Clinical Studies
Table 6.17 CRLX101: Clinical Trial Endpoints (Phase II Studies)
Table 6.18 CRLX101: Clinical Trial Endpoints (Phase I/II Studies)
Table 7.1 Polymer Drug Conjugates: Market Potential of Candidates
Table 7.2 NKTR-181: Target Patient Population
Table 7.3 NKTR-102: Target Patient Population
Table 7.4 CRLX101: Target Patient Population
Table 7.5 Opaxio™: Target Patient Population
Table 7.6 Dendrimers: Opportunity Areas
Table 7.7 Drug Delivery Systems: Example List
Table 7.8 Commercialized Dendrimer-Based Kits
Table 9.1 Pipeline Analysis: Distribution by Phase of Development
Table 9.2 Pipeline Analysis: Distribution by Type of Disease Area
Table 9.3 Pipeline Analysis: Distribution by Type of Polymer
Table 9.4 Pipeline Analysis: Distribution by Type of Drug
Table 9.5 Polymer Drug Conjugates: Key Players
Table 9.6 Nektar Therapeutics: Annual Revenue, 2010-2015 (USD Million)
Table 9.7 Polymer Drug Conjugates Market, Late Clinical Molecules (USD Million): 2016-2026 (Base Scenario)
Table 9.8 Polymer Drug Conjugates Market, Late Clinical Molecules (USD Million): 2016-2026 (Optimistic Scenario)
Table 9.9 Polymer Drug Conjugates Market, Late Clinical Molecules (USD Million): 2016-2026 (Conservative Scenario)
Table 9.10 Polymer Drug Conjugates Market: Share of Lead Molecules in 2026 (USD Million, %)
Table 9.11 NKTR-181 Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Base Scenario)
Table 9.12 NKTR-181 Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Optimistic Scenario)
Table 9.13 NKTR-181 Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Conservative Scenario)
Table 9.14 NKTR-181 Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Base Scenario)
Table 9.15 NKTR-181 Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Optimistic Scenario)
Table 9.16 NKTR-181 Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Conservative Scenario)
Table 9.17 NKTR-102 Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Base Scenario)
Table 9.18 NKTR-102 Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Optimistic Scenario)
Table 9.19 NKTR-102 Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Conservative Scenario)
Table 9.20 NKTR-102 Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Base Scenario)
Table 9.21 NKTR-102 Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Optimistic Scenario)
Table 9.22 NKTR-102 Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Conservative Scenario)
Table 9.23 CRLX101 Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Base Scenario)
Table 9.24 CRLX101 Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Optimistic Scenario)
Table 9.25 CRLX101 Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Conservative Scenario)
Table 9.26 CRLX101 Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Base Scenario)
Table 9.27 CRLX101 Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Optimistic Scenario)
Table 9.28 CRLX101 Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Conservative Scenario)
Table 9.29 Opaxio™ Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Base Scenario)
Table 9.30 Opaxio™ Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Optimistic Scenario)
Table 9.31 Opaxio™ Sales Forecast (USD Million), Short Mid-Term Forecast: 2016-2021 (Conservative Scenario)
Table 9.32 Opaxio™ Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Base Scenario)
Table 9.33 Opaxio™ Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Optimistic Scenario)
Table 9.34 Opaxio™ Sales Forecast (USD Million), Long Term Forecast: 2021-2026 (Conservative Scenario)
Table 9.35 Polymer Drug Conjugates Market, Late Clinical Molecules (USD Million): 2017, 2021, 2026
The following companies and organizations have been mentioned in this report.